Squamous Non-Small Cell Lung Cancer (sqNSCLC) – Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025

Squamous Non-Small Cell Lung Cancer (sqNSCLC) Emerging Therapy and TPP Insights

Thelansis’s “Squamous Non-Small Cell Lung Cancer (sqNSCLC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Squamous Non-Small Cell Lung Cancer (sqNSCLC) Overview

Squamous Non-Small Cell Lung Cancer (sqNSCLC) is a subtype of non-small cell lung cancer, which is one of the two main categories of lung cancer. This particular form originates in the squamous cells, which are flat, thin cells that line the inside of the airways in the lungs. It is often associated with a history of smoking and tends to develop in the central part of the lungs, near the main airways or bronchi. The disease is characterized by its aggressive nature and its tendency to cause symptoms such as persistent coughing, chest pain, shortness of breath, and coughing up blood. As the cancer progresses, it may lead to systemic symptoms like unexplained weight loss, fatigue, and loss of appetite. In advanced stages, sqNSCLC can metastasize, spreading to other parts of the body such as the bones, brain, or liver, which can result in additional complications and symptoms.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key emerging therapies – profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Current challenges
  • Unmet needs
• Emerging therapies
  • Key therapies vs. focused patient segment
  • Key attributes and benefits
  • Futures treatment landscape
  • Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)